Sector Gamma AS increased its position in Elanco Animal Health (NYSE:ELAN) by 125.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 417,042 shares of the company’s stock after acquiring an additional 232,000 shares during the quarter. Elanco Animal Health comprises approximately 1.9% of Sector Gamma AS’s holdings, making the stock its 21st biggest position. Sector Gamma AS owned about 0.11% of Elanco Animal Health worth $11,089,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Winthrop Partners WNY LLC purchased a new stake in Elanco Animal Health in the 3rd quarter worth approximately $25,000. Steward Partners Investment Advisory LLC purchased a new stake in Elanco Animal Health during the 2nd quarter valued at approximately $32,000. Capital Investment Advisory Services LLC grew its holdings in Elanco Animal Health by 1,501.4% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 1,121 shares of the company’s stock valued at $36,000 after buying an additional 1,051 shares in the last quarter. San Francisco Sentry Investment Group CA grew its holdings in Elanco Animal Health by 196.7% during the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,157 shares of the company’s stock valued at $31,000 after buying an additional 767 shares in the last quarter. Finally, Toth Financial Advisory Corp purchased a new stake in Elanco Animal Health during the 3rd quarter valued at approximately $33,000.
A number of brokerages have issued reports on ELAN. Bank of America lowered shares of Elanco Animal Health from a “buy” rating to a “neutral” rating and set a $30.00 price objective for the company. in a report on Monday, August 26th. Zacks Investment Research lowered shares of Elanco Animal Health from a “hold” rating to a “sell” rating in a report on Tuesday, October 15th. ValuEngine raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Goldman Sachs Group began coverage on shares of Elanco Animal Health in a report on Monday, September 9th. They set a “positive” rating for the company. They noted that the move was a valuation call. Finally, Barclays began coverage on shares of Elanco Animal Health in a report on Monday, September 23rd. They set an “overweight” rating and a $36.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. Elanco Animal Health currently has an average rating of “Hold” and an average target price of $33.41.
In related news, Director Deborah Turner Kochevar purchased 1,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was bought at an average cost of $27.95 per share, for a total transaction of $27,950.00. Also, major shareholder Dawei Li purchased 1,384,717 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was bought at an average price of $1.05 per share, with a total value of $1,453,952.85. Over the last three months, insiders purchased 1,497,497 shares of company stock valued at $4,457,115. 0.04% of the stock is currently owned by insiders.
Shares of ELAN stock traded up $0.31 on Friday, reaching $27.23. The company’s stock had a trading volume of 3,676,022 shares, compared to its average volume of 5,298,131. The stock’s fifty day simple moving average is $26.87 and its 200-day simple moving average is $30.28. Elanco Animal Health has a 1 year low of $25.51 and a 1 year high of $35.46. The company has a current ratio of 3.07, a quick ratio of 1.71 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $10.03 billion, a price-to-earnings ratio of 23.08 and a beta of 0.69.
Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, November 6th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.04. Elanco Animal Health had a net margin of 4.69% and a return on equity of 7.83%. The firm had revenue of $771.30 million during the quarter, compared to analyst estimates of $765.85 million. During the same period last year, the firm posted $0.29 earnings per share. Elanco Animal Health’s revenue for the quarter was up 1.3% compared to the same quarter last year. Equities research analysts forecast that Elanco Animal Health will post 1.08 earnings per share for the current year.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.
Read More: Hedge Funds – Risk or Reward?
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.